Pulmonary Function Testing (PFT) is a critical tool in diagnosing and managing patients with respiratory diseases. However, its interpretation can be complex and requires a comprehensive understanding of respiratory physiology. This article aims to provide a comprehensive guide to the interpretation of PFT.
Parameters such as Forced Vital Capacity (FVC), Forced Expiratory Volume in one second (FEV1), and FEV1/FVC ratio are fundamental in PFT interpretation. FVC reflects the maximum volume of air that can be forcibly exhaled, while FEV1 measures the volume exhaled during the first second. The FEV1/FVC ratio is essential in differentiating between obstructive and restrictive lung diseases.
Spirometry is a key component of PFT. A reduced FEV1/FVC ratio (<70%) indicates obstructive lung disease. If this ratio is normal or high, but FVC and FEV1 are reduced, a restrictive pattern is suggested. The severity of the disease can be assessed by the degree of reduction in FEV1.
Measurement of lung volumes can help confirm restrictive diseases when spirometry is inconclusive. A reduced Total Lung Capacity (TLC) indicates restrictive lung disease. The Diffusion Capacity of the Lung for Carbon Monoxide (DLCO) assesses the gas exchange capacity of the lung. A decreased DLCO may suggest interstitial lung disease or pulmonary vascular disease.
Interpretation of PFT should always be integrated with clinical context. Serial PFTs can be used to monitor disease progression or response to treatment. It is also essential in preoperative evaluation and disability assessment.
Interpreting PFT is a multifaceted process that requires a solid understanding of respiratory physiology and clinical correlation. Understanding the basic principles of PFT interpretation can significantly enhance clinical decision-making in patients with respiratory diseases.
1.
When does a melanoma metastasize? Implications for management
2.
Asandeutertinib Tops Osimertinib for NSCLC With Brain Mets
3.
Mammography with AI support is a secure method for detecting breast cancer.
4.
Compared to previous estimates, a greater number of patients participate in cancer treatment trials.
5.
The biology of cancer as well as potential treatment options are examined by experts.
1.
Case Study: Diagnostic and Therapeutic Challenges in Aplastic Anemia Mimicking Hypoplastic Myelodysplastic Syndrome
2.
HPV and Immunotherapy in Cancer Survivorship: National Cancer Survivors Day Review
3.
Tumor-Associated Stroma Regeneration Models
4.
Colorectal Cancer Incidence Trends: A Growing Concern in 2024 and 2025
5.
Immunotherapy Tolerance in Older Adults With Cancer
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation